Seaport Therapeutics closed at $20.39 on Nov 5, down 2.72%, 17.4% below its highest close since Sep 11. Volume of 221.1K shares was 0.93× its 20-day average (close to normal).
Split-adjusted performance: +13.7% over one month.
Short interest was 3.7M shares at the Oct 15 settlement, up 1.9% from the prior report (19.2% of float, 17.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −28.4%, revenue growth +5.9%, net margin −38.9%, P/E 15.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SPTXSeaport Therapeutics | $20.39 | −2.72% | — | — | — | — | $1.09B | |
| VSTMVerastem | $9.38 | −4.77% | +65.7% | +1775.4% | −86.5% | — | $1.14B | Compare |
| MRVIMaravai LifeSciences Holdings | $6.98 | −9.59% | +77.2% | +8.5% | −24.1% | — | $1.04B | Compare |
| AMPHAmphastar Pharmaceuticals | $27.66 | −1.28% | +15.1% | +5.4% | 16.5% | 15.0 | $1.18B | Compare |
| AVLNAvalyn Pharma | $26.67 | −2.91% | — | — | — | — | $1.18B | Compare |
| MNKDMannkind | $3.76 | −4.33% | +5.9% | +42.9% | −17.4% | — | $1.21B | Compare |
| JANXJanux Therapeutics | $16.06 | −11.66% | +10.5% | — | −214.0% | — | $981.9M | Compare |
| HROWHarrow | $26.04 | −9.43% | −33.3% | +10.9% | −24.4% | — | $976.2M | Compare |
| LBRXLB Pharmaceuticals | $38.09 | −6.76% | +19.1% | — | — | — | $1.23B | Compare |
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
